ZyVersa Therapeutics, Inc. Annual Deferred Federal Income Tax Expense (Benefit) in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
ZyVersa Therapeutics, Inc. annual/quarterly Deferred Federal Income Tax Expense (Benefit) history and growth rate from 2022 to 2023.
  • ZyVersa Therapeutics, Inc. Deferred Federal Income Tax Expense (Benefit) for the quarter ending December 31, 2022 was -$152K.
  • ZyVersa Therapeutics, Inc. annual Deferred Federal Income Tax Expense (Benefit) for 2023 was -$19.1M, a 772% decline from 2022.
Deferred Federal Income Tax Expense (Benefit), Annual (USD)
Deferred Federal Income Tax Expense (Benefit), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.